Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 449Neoplasms, Plasma Cell 69Recurrence 42Immunoglobulin Light-chain Amyloidosis 24Neoplasms 12Paraproteinemias 9Lymphoma, Non-Hodgkin 9Leukemia, Lymphocytic, Chronic, B-Cell 9Hematologic Neoplasms 9Renal Insufficiency 8Amyloidosis 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Mantle-Cell 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 7Lymphoma 7Lymphoma, B-Cell, Marginal Zone 6Leukemia, Plasma Cell 6Leukemia, Myeloid, Acute 6Hematologic Diseases 6Waldenstrom Macroglobulinemia 5Lymphoma, Large-Cell, Immunoblastic 5Leukemia 5Burkitt Lymphoma 5Immunoproliferative Disorders 4Hodgkin Disease 4Blood Protein Disorders 4Plasmacytoma 3Peripheral Nervous System Diseases 3Neoplasms by Histologic Type 3

Interventions

Thalidomide 1Dexamethasone 1Bortezomib 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Renal Insufficiency, Chronic × Bortezomib × Plasma cell × Clear all
NCT02424851 2022-01-27

OPTIMAL

Oxford University Hospitals NHS Trust

Phase 2 Completed
31 enrolled 13 charts
Plasma cell

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡